LATEST NEWS

London, UK – 23 November 2011


Proximagen and Altacor sign agreement for 5HT2c.

 


Read more...

2010 Annual Report


Proximagen’s 2010  Annual Report is now available to download.  To view the report, please click the link below.


Download PDF...

INVESTORS

Investor Relations


Our investor relations centre is provided to give you convenient access to company information.


Read more...

Share Price


Proximagen Group plc (Ticker: PRX) is listed on the London Stock Exchange’s Alternative Investment Market.


View Share Price...

SCIENCE

Commitment to Science


Proximagen's commitment to science is fundamental. We strive for true scientific innovation in treatment.


View our Pipeline...

Therapeutic Areas


Proximagen's aims to be one of the leading companies developing therapeutics in CNS, neuroinflammation, inflammation, and oncology.


Read more...